Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Κατάταξη σε μετοχές #30
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the... AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Τιμή μετοχής
$207.15
Κεφαλαιοποίηση
$366.28B
Αλλαγή (1 ημέρα)
0.99%
Αλλαγή (1 έτος)
2.91%
Χώρα
US
Εμπόριο AbbVie Inc. (ABBV)

Κατηγορία

Έσοδα για την AbbVie Inc. (ABBV)
Έσοδα τον Dec 2025 TTM: $61.16B
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της AbbVie Inc., τα τρέχοντα έσοδα της εταιρείας (TTM) είναι $61.16B. Το 2024, η εταιρεία είχε έσοδα $56.33B αύξηση σε σχέση με τα έσοδα του έτους 2023, τα οποία ήταν $54.32B. Τα έσοδα είναι το συνολικό ποσό που παράγει μια εταιρεία από τις πωλήσεις προϊόντων ή υπηρεσιών. Σε αντίθεση με τα κέρδη, δεν αφαιρούνται έξοδα.
Ιστορικό εσόδων για την AbbVie Inc. από 2009 έως 2026
Έσοδα στο τέλος κάθε έτους
Έτος Έσοδα Αλλαγή
2026 (TTM) $61.16B 0.00%
2025 $61.16B 8.57%
2024 $56.33B 3.71%
2023 $54.32B -6.44%
2022 $58.05B 3.30%
2021 $56.20B 22.69%
2020 $45.80B 37.69%
2019 $33.27B 1.57%
2018 $32.75B 16.08%
2017 $28.22B 10.06%
2016 $25.64B 12.16%
2015 $22.86B 14.52%
2014 $19.96B 6.23%
2013 $18.79B 2.23%
2012 $18.38B 5.37%
2011 $17.44B 11.55%
2010 $15.64B 10.02%
2009 $14.21B 0.00%
Έσοδα για παρόμοιες εταιρείες ή ανταγωνιστές
Εταιρεία Έσοδα Διαφορά Εσόδων Χώρα
$65.18B 6.57%
US
$58.74B -3.96%
GB
$94.19B 54.01%
US
$56.15B -8.19%
CH
$65.01B 6.30%
US